Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy for acromegaly.

P M Stewart1

  • 1Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK B15 2TH. p.m.stewart@bham.ac.uk

Trends in Endocrinology and Metabolism: TEM
|February 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.

European journal of endocrinology·2022
Same author

Acromegaly.

QJM : monthly journal of the Association of Physicians·2016
Same author

Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT).

The Journal of clinical endocrinology and metabolism·2015
Same author

Central hypoadrenalism.

The Journal of clinical endocrinology and metabolism·2014
Same author

Expression of 11β-hydroxysteroid dehydrogenase type 1 in the human hypothalamus.

Journal of neuroendocrinology·2013
Same author

Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue.

Nutrition & diabetes·2012
Same journal

HDL resuscitates cells from ferroptosis.

Trends in endocrinology and metabolism: TEM·2026
Same journal

2-Methylbutyrylcarnitine (2MBC).

Trends in endocrinology and metabolism: TEM·2026
Same journal

Decoding growth hormone actions on human growth plate stem cells.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Androgen loss backfires: Brain gate for tumor immunity.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Glucocorticoid resistance-induced inflammation drives cardiovascular-kidney-metabolic (CKM) syndrome pathophysiology.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Hippo signalling in cellular and tissue-level metabolism across health and disease.

Trends in endocrinology and metabolism: TEM·2026
See all related articles

Acromegaly treatment aims to lower growth hormone (GH) levels, improving patient wellbeing and mortality. Surgery is the primary approach, with medical therapies like somatostatin analogues and Pegvisomant offering effective alternatives or adjuncts.

Area of Science:

  • Endocrinology
  • Oncology

Background:

  • Acromegaly, a disorder caused by excess growth hormone (GH), leads to significant morbidity and reduced life expectancy.
  • Lowering GH levels is crucial for improving patient wellbeing and long-term outcomes.

Purpose of the Study:

  • To review current therapeutic strategies for acromegaly, including surgical and medical options.
  • To discuss the efficacy of various treatments in achieving biochemical control (GH < 2.5 µg/L) and normalizing IGF-I levels.

Main Methods:

  • Review of existing literature on acromegaly treatment modalities.
  • Analysis of data on surgical outcomes and the effectiveness of somatostatin analogues and Pegvisomant.

Main Results:

  • Transsphenoidal surgery can achieve biochemical cure in approximately 60% of patients when performed by experienced surgeons.

Related Experiment Videos

  • Long-acting somatostatin analogues (octreotide, lanreotide) normalize GH and IGF-I in 55-65% of patients.
  • Pegvisomant, a GH receptor antagonist, shows promising clinical and biochemical efficacy.

    • Conclusions:

    • Surgery remains the initial treatment of choice for acromegaly in experienced centers.
    • Medical therapies are effective adjuncts to surgery or radiotherapy and may be considered for primary treatment in the future.
    • Achieving GH levels below 2.5 µg/L is a key therapeutic goal associated with improved mortality.